文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

伊洛福酶α在脓毒症相关急性肾损伤患者中的表型特异性疗效

Phenotype-specific therapeutic efficacy of ilofotase alfa in patients with sepsis-associated acute kidney injury.
PubMed 文献 · Crit Care · 2024-02-19
一句话结论在REVIVAL试验的二次分析中,伊洛福酶α仅使病情更重、肾功能更差的表型2患者90天主要肾脏不良事件显著减少(54% vs 68%,p=0.013),表型1患者无获益(49% vs 46%,p=0.54)。

该研究基于REVIVAL试验650例患者中的570例数据,采用逐步机器学习方法识别与伊洛福酶α疗效相关的临床表型。首先筛选在主次要终点(第90天主要肾脏不良事件,MAKE90)各四分位数间风险比随治疗变化而递增或递减的临床变量,再用线性回归确定疗效大小,最后用前15个变量进行不同聚类分析并行共识评估。最优聚类模型包含两个表型:表型1疾病严重度评分较低、肾与肺功能障碍较轻;表型2严重度评分和肌酐更高、eGFR和碳酸氢盐更低。与安慰剂相比,伊洛福酶α显著减少表型2患者的MAKE90事件(54% vs 68%,p=0.013),而表型1患者无显著差异(49% vs 46%,p=0.54)。作者认为该结果提示伊洛福酶α在更同质患者群体中的治疗潜力,可指导未来试验的患者选择。

要点

  • 在570例REVIVAL试验患者的聚类分析中,表型2患者接受伊洛福酶α后MAKE90发生率为54%,安慰剂组为68%(p=0.013)。
  • 表型1患者接受伊洛福酶α后MAKE90发生率为49%,安慰剂组为46%(p=0.54),两组无显著差异。
  • 表型2特征为疾病严重度评分更高、肌酐更高、eGFR更低、碳酸氢盐更低;表型1疾病严重度评分较低、肾与肺功能障碍较轻。
  • 作者认为,病情更重且存在基础肾脏疾病的患者从伊洛福酶α治疗中获益最大。
  • 该表型分析结果可能指导未来试验中SA-AKI患者的筛选。

适用人群与场景

  • REVIVAL试验纳入的脓毒症相关急性肾损伤(SA-AKI)患者,共650例中的570例用于本分析。

研究设计与关键结果

  • 研究类型:基于REVIVAL试验数据的二次分析,采用逐步机器学习方法(先筛选MAKE90风险比随治疗变化的变量,再线性回归确定疗效大小,最后用前15个变量聚类并行共识评估)。
  • 样本量:570例(来自REVIVAL试验650例)。
  • 最优聚类模型包含两个表型:表型1疾病严重度评分相对较低,肾和肺功能障碍较轻;表型2严重度评分和肌酐更高,eGFR和碳酸氢盐更低。
  • 主要终点(MAKE90):表型2患者伊洛福酶α组54% vs 安慰剂组68%,p=0.013;表型1患者伊洛福酶α组49% vs 安慰剂组46%,p=0.54。

证据类型、等级与局限

  • 证据类型:基于随机对照试验REVIVAL数据的二次分析(机器学习聚类分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,该研究识别出的病情更重且存在基础肾脏疾病的临床表型患者从伊洛福酶α治疗中获益最大,该结果可指导未来试验中的患者选择。

指南或共识出处

  • REVIVAL试验

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: There is no effective treatment for sepsis-associated acute kidney injury (SA-AKI). Ilofotase alfa (human recombinant alkaline phosphatase) has been shown to exert reno-protective properties, although it remains unclear which patients might be most likely to benefit. We aimed to identify a clinical phenotype associated with ilofotase alfa's therapeutic efficacy.

METHODS: Data from 570 out of 650 patients enrolled in the REVIVAL trial were used in a stepwise machine learning approach. First, clinical variables with increasing or decreasing risk ratios for ilofotase alfa treatment across quartiles for the main secondary endpoint, Major Adverse Kidney Events up to day 90 (MAKE90), were selected. Second, linear regression analysis was used to determine the therapeutic effect size. Finally, the top-15 variables were used in different clustering analyses with consensus assessment.

RESULTS: The optimal clustering model comprised two phenotypes. Phenotype 1 displayed relatively lower disease severity scores, and less pronounced renal and pulmonary dysfunction. Phenotype 2 exhibited higher severity scores and creatinine, with lower eGFR and bicarbonate levels. Compared with placebo treatment, ilofotase alfa significantly reduced MAKE90 events for phenotype 2 patients (54% vs. 68%, p = 0.013), but not for phenotype 1 patients (49% vs. 46%, p = 0.54).

CONCLUSION: We identified a clinical phenotype comprising severely ill patients with underlying kidney disease who benefitted most from ilofotase alfa treatment. This yields insight into the therapeutic potential of this novel treatment in more homogeneous patient groups and could guide patient selection in future trials, showing promise for personalized medicine in SA-AKI and other complex conditions.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Bruse N, Pardali K, Kraan M, et al. Phenotype-specific therapeutic efficacy of ilofotase alfa in patients with sepsis-associated acute kidney injury. Crit Care. 2024. PMID: 38373981. doi:10.1186/s13054-024-04837-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。